Prognostic value of Pheochromocytoma of the adrenal gland scaled score (Pass score) tests to separate benign from malignant neoplasms
##plugins.themes.academic_pro.article.main##
Abstract
Background: Differentiating malignant from benign pheochromocytoma has been challenging when based on histologic features. This is due to the definition of malignant pheochromocytoma which are defined by the presence of metastases. A PASS score was developed and according to many authors, a PASS score> =4 identified potentially malignant tumors.
aim: To assess the prognostic value of PASS score in differentiating benign pheochromocytomas from malignant ones.
methods: The records of 11 patients with tumors diagnosed as “pheochromocytoma” were identified from 1970 to 2010 in the files of the pathology, intern medicine and biochemistry departments of the Charles Nicolle hospital and Pasteur Institute. Receiver operating characteristics (ROC) curve analysis was performed to evaluate the diagnostic performance of PASS. The logistic model was developed using the 11 predictive variables. Its performance was evaluated by calculating the area under the ROC curve and comparing it with that of the PASS.
results: In benign tumors, The PASS score was <4 in 3 cases and >=4 in 6 cases. In malignant tumors, the PASS score was >=4 in both cases. According to the ROC curve analysis, a PASS equal or superior to 4 identifies malignant pheochromocytoma with a sensitivity of 50% and a specificity of 45%.
Conclusion: I think that PASS score, despite its low sensitivity, may help to reserve the more aggressive treatment and narrow follow up for potentially malignant tumors. Widespread of this called score with complete clinical data will help to validate these findings and to add other prognostic factors of value that could be a part of this scaled score such as immunohistochemical findings.
aim: To assess the prognostic value of PASS score in differentiating benign pheochromocytomas from malignant ones.
methods: The records of 11 patients with tumors diagnosed as “pheochromocytoma” were identified from 1970 to 2010 in the files of the pathology, intern medicine and biochemistry departments of the Charles Nicolle hospital and Pasteur Institute. Receiver operating characteristics (ROC) curve analysis was performed to evaluate the diagnostic performance of PASS. The logistic model was developed using the 11 predictive variables. Its performance was evaluated by calculating the area under the ROC curve and comparing it with that of the PASS.
results: In benign tumors, The PASS score was <4 in 3 cases and >=4 in 6 cases. In malignant tumors, the PASS score was >=4 in both cases. According to the ROC curve analysis, a PASS equal or superior to 4 identifies malignant pheochromocytoma with a sensitivity of 50% and a specificity of 45%.
Conclusion: I think that PASS score, despite its low sensitivity, may help to reserve the more aggressive treatment and narrow follow up for potentially malignant tumors. Widespread of this called score with complete clinical data will help to validate these findings and to add other prognostic factors of value that could be a part of this scaled score such as immunohistochemical findings.
Keywords:
PASS score, pheochromocytoma, prognosis, microscopy##plugins.themes.academic_pro.article.details##
References
- Poll H. Die vergleichende Entwicklung der nebennierensysteme. In: Hertwig O, ed. Handbuch der Entwicklungsgeschichte des Menschen und der Wirbeltiere. Jena: Gustave Fischer, 1905:443-8.
- Samaan NA, Hickey RC, Shutts PE. Diagnosis, localization and management of pheochromocytoma: pitfalls and follow up in 41 patients. Cancer 1988;62:2451-60.
- Thompson LDR, Young WF, Kawashima A, Komminoth P, Tischler AS. Malignant adrenal pheochromocytoma. In: DeLellis RA, Lioyd RV, Heitz PU, Eng C.World Health Organization Classification of tumours: Tumours of endocrine organs. IARC Press Lyon, 2004:147-151.
- Frankel F. Ein Fall von doppelseitigem, vollig latent verlaufenen Nebennierentumor und gleichzeitiger Nephritis mit Veranderungen am Circulationsapparat und Retinitis. Arch Pathol Anat Physiol Klin Med 1886;103:244-63.
- Hartmut PH, Neurmann M, Vortmeyer A, et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 2007;27:1311-15.
- Koch CA, Vortmeyer AO, Huang SC, Alesci S, Zhuang Z, Pacak K. Genetic aspects of pheochromocytoma. Endocr Regul 2001;35:43-52.
- Meyer-Rochow G, Smith JM, Richardson AL, et al. Denaturing High Performance Liquid Chromatography Detection of SDHB, SDHD, and VHL Germline Mutations in Pheochromocytoma. J Surg Res 2009;3:1-8.
- Neumann HP, Bausch B, Mc Whinney SR, et al. Germ-line mutations in, nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459.
- Amar L, Berthera t J, Baudin E, et al. Genetic tes ting in pheochr o m o cytoma or functiona l para g angli o m a. J C lin Oncol 2005;23:8812
- Qin Y, Yao L, King E, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature genetics 2010;42:229-35.
- Medeiros LJ , Wolf B C, Bal g oh K, Federm an M . A d renal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985;16:580-9
- Melicow MM. One hundred cases of pheochromocytoma (107 tumors) a t th e Columbia -Pre byt erian Medical center, 19 26-1976 . Cancer 1977;40:1987-99.
- Mirallié E, Cariou B, Kraeber-Bodéré F. bilateral pheochromocytoma. Genetics and treatment. Ann Chir 2005; 130:273-76
- Scott HWJ, Reynolds V, Green N, et al. Clinical experience with malignant pheochromocytomas. Surg Gynecol Obstet 1982;154:801-18.
- Opocher G, Schiavi F, Cicala MV, et al. Genetics of adrenal tumors. Minerva Endocrinol 2009;34:107-21.
- Thompson LDR. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms. Am J Surg Pathol 2002;26:551-66
- Modlin IM, farndon JR, Shepherd A, et al. Pheochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg 1979;66:456-65.
- Orchard T, Grant CS, Van Heerden JA, Weaver A. Pheochromocytoma: continuing evolution of surgical therapy. Surgery 1993;114:1153-9.
- Pommier RF, Vetto JT, Billingsly K, Woltering EA, Brennan MF. Comparison of adrenal and extra adrenal pheochromocytomas. Surgery 1993;114:1160-6.
- Samaan NA, Hickey RC, Shutts PE. Diagnosis, localization, and management of pheochromocytoma: pi tfalls and follow-up in 41 patients. Cancer 1988;62:2451-60.
- Scopsi L, Castellani MR, Gullo M, et al. Malignant pheochromocytoma in multiple endocrine neoplasia type 2b syndrome: case report and review of the literature. Tumori 1996;82:480-4.
- Westfried M, Mandel D, Alderete MN, Groopman J, Minkowitz S. Sipple's syndrome with a malignant pheochromocytoma presenting as a pericardial effusion. Cardiology 1978;63:305-11.
- Gao B, Meng F, Bian W, et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 2006;68:282-6.
- Amar L, Baudin E, Burnichon N, et al. Succinate Dehydrogenase B Gene Muta tions Pred ict Survival in pat ient s with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822-28
- Scott HWJ, Reynolds V, Green N et al. Clinical experience with malignant pheochromocytoma. Surg Gynecol Obstet 1982;154:801-18.
- Bornstein SR, Gimenez- Roqueplo AP. Genetic te sting in pheo chromocyt om a: Increasing importance for cl inic al de cision making. Ann N Y Acad Sci 2006;1073:94.
- Van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with p araganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10:764-71.
- Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large series of patients with paragangliomas. J Clin Endocrinol Metab 2009;94:2817-27.